Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3NET 1Gynecologic 1Endocrine 1

Conditions

Ovarian Neoplasms 106Fallopian Tube Neoplasms 48Carcinoma, Ovarian Epithelial 31Uterine Cervical Neoplasms 28Pancreatic Neoplasms 13Endometrial Neoplasms 13Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Recurrence 7Prostatic Neoplasms 7Neoplasm Metastasis 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Sarcoma 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Peritoneal Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Melanoma 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Vulvar Neoplasms 3Uterine Neoplasms 3Multiple Myeloma 3Carcinoma 3

Interventions

pembrolizumab 2belinostat 2taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1Fluorouracil 1Etoposide 1Drug Therapy 1Cisplatin 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Gemcitabine × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡